LQDA

AI Memo

Liquidia

As of 2026-10-01/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-01 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Court remedy for YUTREPIA patent infringement • 2026-10-07

Base target: $28 / p=40% prob

Biggest risk

A broader product interruption, delayed relabeling, or damages could impair the dominant commercial asset. United Therapeutics says it will seek FDA withdrawal of the current approval and monetary damages; those are its requested outcomes, not remedies the court has granted. United Therapeutics release

Invalidation

Break below $10 or thesis failure.

What would change my mind?

A remedy limited to PH-ILD labeling, continued PAH availability, and a successful appeal could preserve substantial value in the franchise. The pre-ruling Q2 sales and profitability demonstrate commercial traction, but cannot establish post-ruling earnings power. [#SEC-8K-2026-08-12] [#PR-2026-09-30]

Research note

Recommendation

—

Confidence

high

As of

2026-10-01

Base target

$28

p=40%

Bull target

$55

p=25%

Bear target

$10

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

YUTREPIA commercial durability under a narrower label
L606 Re-Spire clinical development
A remedy limited to PH-ILD labeling, continued PAH availability, and a successful appeal could preserve substantial value in the franchise.

BearKey bullets

A remedy could extend beyond removing PH-ILD from the label and restrict YUTREPIA availability more broadly.
[#PR-2026-09-30]
Pre-ruling sales, profitability, and analyst forecasts may overstate earnings under a restricted label.

WatchKey bullets

Court remedy for YUTREPIA patent infringement

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $28 (p=40%)

Target spread vs base: +96% / -64%

Scenario probabilities

Bull Target: $55 (p=25%)Base Target: $28 (p=40%)Bear Target: $10 (p=35%)

Commentary

The September 30 court decision overwhelmed the earlier positive Q2 commercial update: LQDA closed at $30.26, down about 57% for the day. This is an estimate of the observed reaction, not proof that every remedy is priced in. One target cut is reported, but comprehensive post-ruling estimate revisions remain unavailable. Social, options-skew, short-interest, and employee measures are unavailable; zeros are placeholders, not neutral readings. Price history Analyst revisions

As of 2026-10-01 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

YUTREPIA commercial durability under a narrower label
L606 Re-Spire clinical development

Scenarios

Bull Target (Scenario probability)

$55 / p=25% prob

Base Target (Scenario probability)

$28 / p=40% prob

Bear Target (Scenario probability)

$10 / p=35% prob

Analysis 2026-10-01 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.85

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-07
Court remedy for YUTREPIA patent infringement
A Delaware court found two asserted patent claims valid and infringed. The parties must submit proposed judgment terms within one week of September 30; that is a submission deadline, not a confirmed ruling date. Liquidia says the eventual remedy could range from removal of the PH-ILD indication to broader restrictions on YUTREPIA availability. [#8-K-2026-09-30] [#PR-2026-09-30] Liquidia release
Prob 90.00% • Move -25.00% • Priced-in 55.00%
EVENT2026-12-31
Appeal and proposed PH-ILD label amendment
Liquidia intends to pursue appellate options and submit an FDA supplement removing PH-ILD from YUTREPIA’s label. Neither an appeal outcome nor FDA timing is established; preserving availability for PAH would be less damaging than a broader interruption. [#PR-2026-09-30] Liquidia release
Prob 65.00% • Move 20.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

YUTREPIA commercial durability under a narrower label
2027-06-30
Second-quarter YUTREPIA net sales were $170.4 million, up 31% sequentially, with more than 5,000 patients treated through July 31. Future uptake and profitability depend heavily on the remedy’s effect on permitted sales; the disclosed figures predate the adverse ruling. [#SEC-8K-2026-08-12]
Prob 55% • Move 18% • Priced-in 45%
L606 Re-Spire clinical development
2027-12-31
Liquidia reported site activation and enrollment in its pivotal L606 Re-Spire study. This is a longer-horizon development option, not an established offset to immediate YUTREPIA litigation exposure; no readout date was supplied. [#SEC-8K-2026-08-12]
Prob 55% • Move 15% • Priced-in 25%

Risks

A remedy could extend beyond removing PH-ILD from the label and restrict YUTREPIA availability more broadly. [#PR-2026-09-30]
Pre-ruling sales, profitability, and analyst forecasts may overstate earnings under a restricted label. [#SEC-8K-2026-08-12]
The company says potential financial exposure cannot yet be reasonably estimated; appeals and FDA relabeling add timing and execution risk. [#PR-2026-09-30]
The court found two PH-ILD-related patent claims valid and infringed; the scope and timing of the remedy remain unresolved. [#PR-2026-09-30]

Peers

Symbol	Summary
BEAM	Similar market-cap biotechnology candidate in the packet, but not a demonstrated inhaled-treprostinil operating peer; unsuitable for a direct valuation multiple.
UTHR	Direct inhaled-treprostinil competitor and patent plaintiff; its Tyvaso products compete in PH-ILD. It is more relevant than same-sector market-cap peers, but its larger, diversified business limits valuation comparability. United Therapeutics release

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-01

Loading AI feed…

Symbol

Summary

BEAM

Similar market-cap biotechnology candidate in the packet, but not a demonstrated inhaled-treprostinil operating peer; unsuitable for a direct valuation multiple.

UTHR

Direct inhaled-treprostinil competitor and patent plaintiff; its Tyvaso products compete in PH-ILD. It is more relevant than same-sector market-cap peers, but its larger, diversified business limits valuation comparability. United Therapeutics release